MRK
Price
$84.01
Change
+$0.80 (+0.96%)
Updated
Aug 29, 04:10 PM (EDT)
Capitalization
207.84B
62 days until earnings call
NVS
Price
$126.38
Change
-$0.09 (-0.07%)
Updated
Aug 29, 04:10 PM (EDT)
Capitalization
244.54B
60 days until earnings call
Interact to see
Advertisement

MRK vs NVS

Header iconMRK vs NVS Comparison
Open Charts MRK vs NVSBanner chart's image
Merck & Co
Price$84.01
Change+$0.80 (+0.96%)
Volume$3.53K
Capitalization207.84B
Novartis AG
Price$126.38
Change-$0.09 (-0.07%)
Volume$300
Capitalization244.54B
MRK vs NVS Comparison Chart in %
Loading...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRK vs. NVS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a StrongBuy and NVS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (MRK: $83.21 vs. NVS: $126.47)
Brand notoriety: MRK: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MRK: 116% vs. NVS: 42%
Market capitalization -- MRK: $207.84B vs. NVS: $244.54B
MRK [@Pharmaceuticals: Major] is valued at $207.84B. NVS’s [@Pharmaceuticals: Major] market capitalization is $244.54B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRK’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 2 green FA rating(s).

  • MRK’s FA Score: 1 green, 4 red.
  • NVS’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than MRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRK’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • MRK’s TA Score: 6 bullish, 3 bearish.
  • NVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MRK is a better buy in the short-term than NVS.

Price Growth

MRK (@Pharmaceuticals: Major) experienced а -3.33% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.92%. For the same industry, the average monthly price growth was +1.19%, and the average quarterly price growth was +11.79%.

Reported Earning Dates

MRK is expected to report earnings on Oct 30, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.92% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($245B) has a higher market cap than MRK($208B). NVS has higher P/E ratio than MRK: NVS (18.44) vs MRK (12.82). NVS YTD gains are higher at: 34.645 vs. MRK (-14.788). MRK has higher annual earnings (EBITDA): 25B vs. NVS (22.7B). MRK has more cash in the bank: 8.62B vs. NVS (7B). NVS has less debt than MRK: NVS (32.6B) vs MRK (35.4B). MRK has higher revenues than NVS: MRK (63.6B) vs NVS (55.2B).
MRKNVSMRK / NVS
Capitalization208B245B85%
EBITDA25B22.7B110%
Gain YTD-14.78834.645-43%
P/E Ratio12.8218.4470%
Revenue63.6B55.2B115%
Total Cash8.62B7B123%
Total Debt35.4B32.6B109%
FUNDAMENTALS RATINGS
MRK vs NVS: Fundamental Ratings
MRK
NVS
OUTLOOK RATING
1..100
7025
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
7713
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5946
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRK's Valuation (9) in the Pharmaceuticals Major industry is in the same range as NVS (14). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (77). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.

NVS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as MRK (100). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as MRK (59). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.

NVS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as MRK (100). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRKNVS
RSI
ODDS (%)
Bearish Trend 2 days ago
51%
Bearish Trend 2 days ago
52%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
40%
Momentum
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
55%
MACD
ODDS (%)
Bullish Trend 2 days ago
45%
Bullish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
44%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
45%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 8 days ago
47%
Bullish Trend 3 days ago
49%
Declines
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 24 days ago
45%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
39%
Aroon
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
31%
View a ticker or compare two or three
Interact to see
Advertisement
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FAN18.840.19
+1.02%
First Trust Global Wind Energy ETF
IAUG27.710.09
+0.33%
Innovator Intl Dev Pwr Bffr ETF - Aug
BDGS33.940.07
+0.21%
Bridges Capital Tactical ETF
EUSB43.740.07
+0.16%
iShares ESG Advanced Ttl USD Bd Mrkt ETF
FNDX25.770.02
+0.08%
Schwab Fundamental U.S. Large CompanyETF

MRK and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRK
1D Price
Change %
MRK100%
-1.02%
PFE - MRK
58%
Loosely correlated
-1.87%
BIIB - MRK
49%
Loosely correlated
-2.72%
ABBV - MRK
49%
Loosely correlated
-0.07%
BMY - MRK
46%
Loosely correlated
-1.57%
NVS - MRK
45%
Loosely correlated
-0.33%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.33%
GSK - NVS
68%
Closely correlated
-1.18%
AZN - NVS
61%
Loosely correlated
+0.08%
PFE - NVS
57%
Loosely correlated
-1.87%
JNJ - NVS
54%
Loosely correlated
-0.76%
SNY - NVS
54%
Loosely correlated
-0.34%
More